NCT01335958View on ClinicalTrials.gov

Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Ovarian Cancer, Pancreatic Cancer
Interventions
DRUG

DMUC5754A

Escalating intravenous dose

Trial Locations (4)

37203

Nashville

73104

Oklahoma City

02114

Boston

02115

Boston

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY